Form 8-K

8-K — AIM ImmunoTech Inc.

Accession: 0001493152-26-036996

Filed: 2026-08-11

Period: 2026-08-11

CIK: 0000946644

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

GRAPHIC (ex99-1_002.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0000946644

2026-08-11

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of The

Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): August 11, 2026

AIM

IMMUNOTECH INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-27072

52-0845822

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer Identification

No.)

2117

SW Highway 484, Ocala, Florida

34473

(Address

of principal executive offices)

(Zip

Code)

Registrant’s

telephone number, including area code: (352) 448-7797

Not

Applicable

(Former

name or former address, if changed since last report.)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐ Written communications

pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material

pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

symbol

Name

of each exchange on which registered

Common Stock, par value

$0.001 per share

AIM

NYSE American

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01

Regulation

FD Disclosure.

August 11, 2026, the online media company Breaking Defense (https://breakingdefense.com)

published an article authored by Thomas K. Equels, the Chief Executive Officer of AIM ImmunoTech Inc. (the “Company”). The

article, titled “Biodefense is force protection: Ready today, prepared for tomorrow,” discusses the importance of military

force readiness, specifically how the Company’s drug Ampligen (rintatolimod) has potential as a broad-spectrum early-onset and/or

prophylactic antiviral therapeutic for Ebola virus disease. The article also discusses Ampligen’s history and potential as a broad-spectrum

early-onset and/or prophylactic antiviral therapeutic in the treatment of COVID-19 and related viruses. A copy of the article is furnished

as Exhibit 99.1 hereto.

The

information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18

of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any

filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Cautionary

Note Regarding Forward-Looking Statements

This

Current Report on Form 8-K, including Exhibit 99.1, contains forward-looking statements within the meaning of Section 27A of the Securities

Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but

are not limited to, statements relating to: the potential of Ampligen as a broad-spectrum prophylactic or early-onset treatment for viral

threats, including Ebola virus disease and coronaviruses; preclinical proof-of-concept findings, which are not evidence of FDA approval

or clinical efficacy in humans; expectations regarding Ampligen’s mechanism of action; the timing and outcome of future clinical

trials, regulatory submissions, or government funding decisions; and the Company’s business strategy and objectives.

Words

such as “believe,” “may,” “will,” “could,” “should,” “estimate,”

“anticipate,” “intend,” “expect,” “potential,” “plan,” “project”

and similar expressions identify forward-looking statements. These statements are based on current expectations and assumptions that

may prove incorrect, and involve risks and uncertainties that could cause actual results to differ materially. Important factors include:

uncertainties in pharmaceutical development, including the risk that preclinical results may not be replicated in clinical trials; regulatory

uncertainties; dependence on government funding; limited financial resources; and competitive and market conditions.

For

additional risk factors, see the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC at

www.sec.gov. All forward-looking statements speak only as of the date hereof, and the Company undertakes no obligation to update

them except as required by law. The Company claims the protection of the safe harbor for forward-looking statements contained in the

Private Securities Litigation Reform Act of 1995.

Item 9.01

Financial

Statements and Exhibits.

(d)

Exhibits

Exhibit

No.

Description

99.1

Article titled “Biodefense is force protection: Ready today, prepared for tomorrow,” dated August 11, 2026.

104

Cover Page Interactive

Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Date: August

11, 2026

AIM

ImmunoTech Inc.

/s/

Thomas K. Equels

Chief Executive Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit 99.1

Biodefense

Is Force Protection: Ready Today, Prepared for Tomorrow

decorated combat aviator and biotech CEO advocates preparing for novel viral threats before the next crisis.

Thomas K. Equels

America

treats biodefense too much like a public health backstop and not enough like military force protection. That must change.

a former Army helicopter gunship pilot who flew more than 300 combat missions, an instructor pilot and a TRADOC project officer, I learned

that readiness is built before the threat appears. The people we send into danger need training, equipment, intelligence, planning and

support before they are asked to take the risk. As CEO of AIM ImmunoTech, I know biological threats require the same mindset.

The

history of warfare teaches us that a biological event does not have to begin as an attack to create serious military consequences. A

natural outbreak, accidental release or deliberate biological incident can affect deployments, base operations, shipboard readiness,

homeland defense and the ability to operate in contested environments. When it is a new viral threat, the force can be exposed before

commanders have enough options to respond.

This

is a multi-faceted problem. AIM ImmunoTech’s Scientific Advisory Board Chairman, COL. W. Neal Burnette, Ph.D., M.S., U.S. Army

(Ret.), described the challenge in Military Medicine in 2008, writing: “Identifying which pathogens pose the greatest

threats to the military and developing an appropriate research and development portfolio of countermeasures are serious scientific, health

care, and fiscal challenges.”

The

practical gap is speed. Biological threats move faster than policy, procurement, budgeting, interagency coordination, government-use

approvals and stockpile decisions. By the time a new viral crisis is visible, the defense community is already behind. Surveillance has

to catch up. Diagnostics may need to be adapted. Therapeutics and vaccines may still be under evaluation and may not yet have U.S. Food

and Drug Administration approval. Manufacturing capacity may be limited. All of this can slow the availability of countermeasures, leaving

commanders with far fewer options in the toolbox than they need.

That

is why broad-spectrum prophylactic antiviral countermeasures should be part of the force protection conversation from the start.

Serious

evaluation of promising prophylactic technology must begin long before a novel virus outbreak. Science requires evidence, discipline,

regulatory care and honest assessment. Broad-spectrum antiviral prophylactics often require government-supported evaluation because access

to lethal virus samples, high-containment laboratories and emergency-use planning is tightly controlled. Developing protection against

unknown future viral threats is difficult without government approval, partnership and support. Government and industry must be proactive,

with appropriate FDA-regulated pathways pursued before an outbreak creates operational urgency.

have seen this challenge from both sides: as a combat veteran who understands the human meaning of readiness and as the CEO of a biotechnology

company involved in antiviral research. The point of a broad-spectrum prophylactic in an emerging outbreak is to help protect troops

in close quarters or deployed to outbreak sites, as well as medical staff exposed to infections. A well-evaluated antiviral prophylactic

tool could help limit the spread of a novel virus for which there is no approved vaccine or specific therapy.

AIM

ImmunoTech | Breaking Defense Sponsor-Supplied Article

The

Ebola virus presents a clear example of why it is important for the Department of War to follow through on positive data with further

steps toward a deployable prophylactic. The recent outbreak of the new Bundibugyo Ebola strain underscores the gap. There is currently

no licensed or effective vaccine, nor an approved specific therapeutic, for Bundibugyo virus disease. Vaccine development, evaluation

and deployment takes time. A broad-spectrum prophylactic could create a meaningful buffer during that wait.

Government-funded

preclinical work at the U.S. Army Medical Research Institute of Infectious Diseases’ Biosafety Level 4 laboratories produced compelling

results involving AIM ImmunoTech’s drug Ampligen (rintatolimod) as a potential prophylactic or early-onset therapy for Ebola. As

described in the peer-reviewed journal Antiviral Research, the study showed 100% survival in one rintatolimod-treated cohort

in a lethal mouse model, compared with 100% mortality in controls. The data also support further evaluation of rintatolimod’s mechanism

of action as a potential broad-spectrum approach across Ebola variants such as Bundibugyo, and AIM is currently seeking government support

for such studies.

Here

are the preclinical proof-of-concept findings in the initial experiment. These data illustrate the larger defense-readiness point: if

promising broad-spectrum antiviral prophylactics are not advanced through appropriate government-supported and FDA-regulated evaluation

pathways, they can remain research findings on the shelf rather than tools available for emergency planning. Promising countermeasure

platforms should be fully evaluated and implemented before a crisis creates urgency, not after.

Preclinical

mouse-model data from USAMRIID/Antiviral Research: rintatolimod-treated cohorts showed survival and reduced disease signs compared with

untreated controls. Findings require further evaluation and do not indicate FDA approval or clinical efficacy. (Antiviral Research)

SARS-CoV-2

(or COVID-19) presented a clear exemplar. Government-funded research at the Institute for Antiviral Research at Utah State University

on potential coronavirus antiviral treatments occurred between the SARS-CoV (or SARS) outbreak of 2003 and the COVID-19 outbreak. Analyses

of this work were published in Antiviral Chemistry & Chemotherapy and Virology. Those preclinical studies

supported further evaluation of Ampligen as a potential early-onset antiviral against SARS-related coronaviruses, but the work did not

advance into a ready government-approved countermeasure before the next crisis arrived.

SARS-CoV-2

is genetically very closely related – in fact almost identical – to SARS-CoV. Thus, the broader lesson and the impact on

force readiness becomes clear: The time to evaluate potential countermeasures is before a related threat becomes a global emergency.

The COVID-19 outbreak aboard the USS Theodore Roosevelt infected approximately 1,200 sailors and disrupted operations of one of America’s

most important military assets. Had the government-funded work at the Institute for Antiviral Research been followed up, perhaps a powerful

prophylactic might have been available to the commander of the USS Theodore Roosevelt. The broader lesson is that commanders need more

evaluated and approved options before an outbreak occurs.

Promising

science should not sit outside the readiness conversation until an outbreak forces action. Defense planners should integrate prophylactic

antiviral countermeasures more directly into force protection planning, right alongside diagnostics, detection systems, protective equipment,

decontamination and operational planning. Promising broad-spectrum prophylactic and early-onset antiviral countermeasure platforms should

be evaluated, approved by the FDA where appropriate, manufactured and stockpiled against priority biological threats that could affect

deployed forces.

For

service members, readiness means protection before exposure. For commanders, it means options before a mission is compromised. For policymakers,

it means building systems that can move before the threat dictates the terms.

AIM

ImmunoTech | Breaking Defense Sponsor-Supplied Article

Biodefense

is force protection.

we believe this, then medical countermeasures must be treated as part of defense readiness, not merely as public health tools we hope

to mobilize after the fact. In Army Aviation, we had a slogan that fits here: “Ready today means prepared for tomorrow.”

The next biological threat will not wait for a procurement cycle, a budget cycle or a perfect moment of consensus. We should not wait

either. Prepare now so we are not found wanting tomorrow.

Author Bio

Thomas

K. Equels is CEO of AIM ImmunoTech. He is a former U.S. Army Chief Warrant Officer, Vietnam combat aviator and two-time recipient

of the Distinguished Flying Cross. His military service is recognized by the Smithsonian National Air and Space Museum’s Wall

of Honor.

Disclosure

Disclosure:

Thomas K. Equels is CEO of AIM ImmunoTech, a biotechnology company involved in immune modulation and antiviral research. Ampligen (rintatolimod)

is not FDA-approved for Ebola virus disease, Bundibugyo virus disease, coronaviruses or any biodefense indication.

Forward-Looking

Statements

This

article contains forward-looking statements subject to risks and uncertainties. Forward-looking statements include, but are not limited

to, statements relating to: the potential of Ampligen as a broad-spectrum prophylactic or early-onset treatment for viral threats, including

Ebola virus disease and coronaviruses; preclinical proof-of-concept findings, which are not evidence of FDA approval or clinical activity;

expectations regarding Ampligen’s mechanism of action as potentially broad-spectrum to Ebola variants, including Bundibugyo; and

the timing and outcome of any future clinical trials, regulatory approvals, government funding decisions or government-supported evaluation

pathways.

Words

such as “believe,” “may,” “will,” “estimate,” “anticipate,” “intend,”

“expect,” “should,” “potential,” “plan,” “project,” and similar expressions

identify forward-looking statements. These statements are based on current expectations and are subject to risks and uncertainties that

could cause actual results to differ materially. The Company does not undertake to update forward-looking statements except as required

by law.

For

risk factors and additional information, see AIM ImmunoTech’s U.S. Securities and Exchange Commission filings at www.sec.gov and

www.aimimmuno.com. For all forward-looking statements, AIM ImmunoTech claims the protection of the safe harbor for forward-looking statements

contained in the Private Securities Litigation Reform Act of 1995.

AIM

ImmunoTech | Breaking Defense Sponsor-Supplied Article

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (242451 bytes)

Download ex99-1_001.jpg

GRAPHIC

Filename: ex99-1_002.jpg · Sequence: 4

Binary file (26532 bytes)

Download ex99-1_002.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Aug. 11, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 11, 2026

Entity File Number

001-27072

Entity Registrant Name

AIM

IMMUNOTECH INC.

Entity Central Index Key

0000946644

Entity Tax Identification Number

52-0845822

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2117

SW Highway 484

Entity Address, City or Town

Ocala

Entity Address, State or Province

Entity Address, Postal Zip Code

34473

City Area Code

(352)

Local Phone Number

448-7797

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value

$0.001 per share

Trading Symbol

AIM

Security Exchange Name

NYSEAMER

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration